Retatrutide, from Soma Corp., is receiving considerable attention as a potential method for metabolic regulation. This innovative compound merges the properties of a GLP-1 receptor activator and a GIP receptor stimulant, intended to simply promote metabolic improvements but also address related metabolic issues . Preliminary clinical data have demo